The anti-inflammatory and anti-catabolic properties of VIP, which were demonstrated in arthritis before, might offer therapeutic potential in OA, but the ability of VIP to promote hyperalgesia in OA joints needs to be more carefully evaluated in order to consider VIP-targeted therapies in OA. This evidence concerns the gene VIP and arthritic joint disease.